Multiple Endocrine Neoplasia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Conditions: Medullary Thyroid Carcinoma; Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2BIntervention: Drug: VandetanibSponsors: National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC)Active, not recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2007 Category: Research Source Type: clinical trials

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Conditions: Medullary Thyroid Carcinoma; Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2BIntervention: Drug: VandetanibSponsors: National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC)Active, not recruiting - verified October 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2007 Category: Research Source Type: clinical trials

Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
Condition: Multiple Endocrine NeoplasiaIntervention: Behavioral: QuestionnaireSponsor: M.D. Anderson Cancer CenterActive, not recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2007 Category: Research Source Type: clinical trials

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Conditions: Multiple Endocrine Neoplasia; Recurrent Thyroid Cancer; Thyroid Gland Medullary CarcinomaInterventions: Drug: sorafenib tosylate; Other: pharmacological study; Other: laboratory biomarker analysisSponsor: National Cancer Institute (NCI)Active, not recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2006 Category: Research Source Type: clinical trials

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Conditions: Multiple Endocrine Neoplasia; Recurrent Thyroid Gland Carcinoma; Thyroid Gland Medullary CarcinomaInterventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Sorafenib TosylateSponsor: National Cancer Institute (NCI)Active, not recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2006 Category: Research Source Type: clinical trials

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Conditions: Multiple Endocrine Neoplasia; Recurrent Thyroid Gland Carcinoma; Thyroid Gland Medullary CarcinomaInterventions: Drug: Sorafenib Tosylate; Other: Pharmacological Study; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Active, not recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2006 Category: Research Source Type: clinical trials